following a full submission:
nivolumab (Opdivo®) is accepted for use within NHSScotland.
Indication under review: in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥4 cm or node positive) non-small cell lung cancer in adults.
In an open-label, randomised, phase III study, the addition of nivolumab to platinum-based chemotherapy as neoadjuvant treatment was associated with significant benefits in event-free survival and pathological complete response in patients with stage IB to IIIA resectable non-small cell lung cancer.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice454KB (PDF)
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2619
- Indication:
In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumours ≥ 4 cm or node positive) non-small cell lung cancer in adults.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 December 2023